The Effect of Xolair on Inhibiting Leukotriene and Cytokine (IL-4 and IL-13) Release From Blood Basophils.

Trial Profile

The Effect of Xolair on Inhibiting Leukotriene and Cytokine (IL-4 and IL-13) Release From Blood Basophils.

Active, no longer recruiting
Phase of Trial: Phase IV

Latest Information Update: 05 Jul 2012

At a glance

  • Drugs Omalizumab (Primary)
  • Indications Allergic rhinitis
  • Focus Therapeutic Use
  • Most Recent Events

    • 05 Jul 2012 Planned end date changed from 1 Nov 2011 to 1 Nov 2012 as reported by ClinicalTrials.gov.
    • 29 Jun 2011 Planned End Date changed from 1 May 2011 to 1 Nov 2011 as reported by ClinicalTrials.gov.
    • 28 Oct 2010 Planned End Date changed from 1 Dec 2008 to 1 May 2011 as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top